Refine by
Oncology Data Articles & Analysis
5 news found
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, ...
ByBayer AG
If data is still missing, xCures can query individual providers outside the network to receive complete records. Going far beyond the structured data, the xCures A.I.-powered platform abstracts knowledge from unstructured data such as physician notes and embedded images such as genomics reports. ...
ByxCures
To do this, MH Guide matches molecular patient data with data derived from one of the largest growing and Molecular Health-owned knowledge platforms (Dataome). ...
Investigational compound LDK378 is a selective inhibitor of ALK[1], a target found in metastatic non-small cell lung cancer (NSCLC) Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serve as basis for first filing in early 2014 FDA designated LDK378 as Breakthrough Therapy in March and a robust clinical development plan is ...
Biopticon Corporation Announces the release of the new version of their innovative TumorManagerTM Program for managing pre-clinical oncology study data Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today released the latest version of ...